Development of Safe, Effective Vaccines for Dengue Virus Disease by Recombinant Baculovirus
Abstract
Outbreaks and major epidemics of dengue continue to afflict human populations, especially in the tropical and subtropical regions of the world. Dengue viruses, transmitted predominantly by mosquito species of the Aedes genus, include four serotypes that are distinguishable by plaque reduction-- neutralization with type specific monoclonal antibodies. Dengue is characterized by fever, rash, severe headache, and joint pain. Its mortality rate is low. However, over the past few decades, a more severe form of dengue, characterized by hemorrhage and shock has been observed with increasing frequency in children and young adults. This severe form of dengue has a high mortality rate. Despite years of intensive research, an effective vaccine is still not available for prevention of dengue infection. For these reasons, research on dengue viruses and development of safe and effective vaccines have been given a high priority by the World Health Organization.... Dengue virus, Genetic engineering, Recombinant DNA, Vaccines, Biotechnology, Diseases, ID, RA I.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 25, 1992
- Accession Number
- ADA264657
Entities
People
- Ching J. Lai
Organizations
- National Institutes of Health